Rate My Professor Greg Walker

Walker's research focuses on the formulation and delivery of bioactive molecules, emphasizing physico-chemical principles that govern absorption, disposition, and efficacy enhancement through delivery systems. He possesses extensive expertise in polymeric drug delivery, biopharmaceutical formulation engineering, project management, and pre-clinical studies, with applications in veterinary and animal health. As a principal investigator, he is a key contributor to three Ministry of Business, Innovation and Employment grants totaling over NZ$19 million, targeting vaccines, novel antimicrobials, and crop bioactives. His scholarly output includes publications such as 'Anaerobiosis and mutations can reduce susceptibility of Pseudomonas aeruginosa to tobramycin without reducing the cellular concentration of the antibiotic' (Pathogens, 2025, with W. Krittaphol et al.), 'A sensitive reverse-phase ultra performance liquid chromatography-tandem mass spectrometry method for the determination of tobramycin in Pseudomonas aeruginosa cell lysate' (Journal of Pharmaceutical & Biomedical Analysis, 2025, with W. Krittaphol et al.), 'A landscape review of controlled release urea products: Patent objective, formulation and technology' (Journal of Controlled Release, 2022, with W. Liu et al.), and 'Low-wavenumber Raman spectral database of pharmaceutical excipients' (Vibrational Spectroscopy, 2020, with K. Bērziņš et al.). Walker has received the $50,000 Proof of Concept Grant from Otago Innovation Limited in 2012 for a medical device aimed at minimizing surgery complications and the $25,000 KiwiNet Emerging Innovator Fund grant in 2016 for developing a prototype electrospinning device for nano-webs. He has presented on topics including 'Bridging the gap: Research collaboration between academia and industry' at the School of Pharmacy Research Symposium in 2024.